Silence Therapeutics plc
NASDAQ:SLNBiotechnology
+$0.19 today
- Market cap
- $936.18M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
Volume 1.47M
Average 0.31M
SLN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Silence Therapeutics plcNASDAQ: SLN
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow shrinks to $0
Q1 FY2026 financing cash flow was $0, compared with $14K a year earlier. Trailing-twelve-month financing cash flow was $911.01. Over 3 fiscal years it compounded at -93.4% a year.
Context
- Financing cash flow amounted to 2.7% of revenue in FY2025, down 259.8 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $227.75.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
Mixed currencies · from the cash flow
- Latest · FY2025
- 15K USD
- Year-over-year change
- —
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15K | — |
| FY2024 | 2024-12-31 | 113.54M | +351.4% |
| FY2023 | 2023-12-31 | 25.16M | -52.2% |
| FY2022 | 2022-12-31 | 52.58M | +26.9% |
| FY2021 | 2021-12-31 | 41.45M | — |
Financing Cash Flow vs competitors
How SLN compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Financing cash flow amounts to 0.1% of revenue for SLN, versus a peer median of 27.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $776.82M USD | +949.7% | +45.3% | 172.3% | |
| LTM Mar 2026 | $489.54M USD | +101.0% | +93.7% | 681.8% | |
| LTM Sep 2026 | $261.93M USD | +546.0% | — | 27.3% | |
| LTM Mar 2026 | $180.57M USD | -256.8% | — | 8.3% | |
| LTM Mar 2026 | $106.87M USD | -1.1% | — | — | |
| FY2025 | $42.57M USD | — | — | 228.7% | |
| LTM Mar 2026 | $1.8M USD | -109.8% | — | 4.0% | |
| LTM Mar 2026 | €1.63M EUR | -102.3% | -61.5% | 12.2% | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding SLN) | — | -1.1% | +45.3% | 27.3% | |
Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · GBP | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (61.89M) | (50.33M) | (50.31M) | (28.92M) | (88.61M) |
| Depreciation & Amortization | 576.29K | 596K | 498K | 473.86K | 555K |
| Deferred Income Tax | 5.95M | 688K | 0 | 675.23K | 11K |
| Stock-Based Compensation | 11.65M | 12.69M | 13.05M | 10.41M | 8.07M |
| Change in Working Capital | 52.43M | (19.4M) | (11.66M) | (26.39M) | 10.16M |
| Accounts Receivables | 37.09M | (10.54M) | 314K | (722.38K) | 5.07M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 15.33M | (8.85M) | (11.98M) | (25.67M) | 5.09M |
| Other Non-Cash Items | 468.32K | (1.28M) | 9.07M | (10.3M) | 7.54M |
| Operating Cash Flow | 9.19M | (57.04M) | (39.35M) | (54.05M) | (62.27M) |
| Capital Expenditures | (1.8M) | (545K) | (45K) | (168.61K) | (55K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (19.95M) | (20.67M) | (111.21M) | (166.41M) |
| Sales of Investments | 13.5M | 0 | 36.18M | 0 | 118.48M |
| Other Investing Activities | (17.55K) | (372K) | 958K | 93.82M | 0 |
| Investing Cash Flow | 11.71M | (20.5M) | 16.43M | (17.55M) | (47.99M) |
| Debt Repayment | (284.77K) | 0 | (174K) | 0 | 0 |
| Common Stock Issued | 41.73M | 52.58M | 25.33M | 113.54M | 15K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.45M | 52.58M | 25.16M | 113.54M | 15K |
| Effect of Forex Changes | (141.71K) | (8.12M) | (3.02M) | 47.95K | 195K |
| Net Change in Cash | 62.2M | (33.08M) | (785K) | 41.98M | (110.05M) |
| Free Cash Flow | 7.39M | (57.59M) | (39.4M) | (54.22M) | (62.33M) |
Silence Therapeutics plc
NASDAQ:SLN
Intrinsic Alpha fair value
Locked
Current Price
$19.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.